查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
蛋白质工程市场：按产品类型、按技术类型、按蛋白质类型、按最终用户：2023-2032 年全球机会分析和产业预测
市场调查报告书
商品编码
1414719

蛋白质工程市场：按产品类型、按技术类型、按蛋白质类型、按最终用户：2023-2032 年全球机会分析和产业预测

Protein Engineering Market By Product, By Technology Type, By Protein Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 295 Pages | 商品交期: 2-3个工作天内

价格

2022年蛋白质工程市值为22亿美元，预计2023年至2032年复合年增长率为13.2%，到2032年将达77亿美元。

蛋白质工程市场-IMG1

可使用此报告进行客製化（需要额外费用和时间表）

  • 根据客户兴趣加入公司简介
  • 公司简介的扩充列表
  • 历史市场资料

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 活性化生物製药产业的研发活动
      • 蛋白质工程技术进展
      • 主要企业加大蛋白质工程发展策略
    • 抑制因素
      • 蛋白质工程系统的高成本与维护
    • 机会
      • 新兴市场的成长机会

第四章蛋白质工程市场：副产品

  • 概述
  • 用具
  • 消耗品
  • 软体

第五章蛋白质工程市场：依技术类型

  • 概述
  • 合理或定点特异性
  • 不合理或随机诱变

第六章蛋白质工程市场：依蛋白质类型

  • 概述
  • 单株抗体
  • 胰岛素
  • 促血红细胞生长素
  • 干扰素
  • 其他的

第七章蛋白质工程市场：依最终用户分类

  • 概述
  • 製药和生物技术公司
  • 学术研究所
  • 受託研究机构

第八章蛋白质工程市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第9章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第十章 公司简介

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • Promega Corporation
  • New England Biolabs, Inc.
  • Danaher Corporation
  • Creative Biolabs Limited
  • Bio-Rad Laboratories, Inc.
  • Amgen, Inc.
  • Jena Bioscience GmbH
  • TAKARA HOLDINGS INC.
Product Code: A00969

According to a new report published by Allied Market Research, titled, "Protein Engineering Market," The protein engineering market was valued at $2.2 billion in 2022, and is estimated to reach $7.7 billion by 2032, growing at a CAGR of 13.2% from 2023 to 2032.

Protein Engineering Market - IMG1

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations

By Product

  • Instruments
  • Consumables
  • Software

By Technology Type

  • Rational or Site Directed Mutagenesis
  • Irrational or Random Mutagenesis

By Protein Type

  • Monoclonal Antibodies
  • Insulin
  • Erythropoietin
  • Interferon
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Agilent Technologies, Inc.
    • Promega Corporation
    • New England Biolabs, Inc.
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Amgen, Inc.
    • TAKARA HOLDINGS INC.
    • Thermo Fisher Scientific Inc.
    • Creative Biolabs Limited
    • Jena Bioscience GmbH

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. High intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increasing research & development activities in the biopharmaceutical industry
      • 3.4.1.2. Technological advancements in protein engineering
      • 3.4.1.3. Increase in developmental strategies in protein engineering by key players
    • 3.4.2. Restraints
      • 3.4.2.1. High cost and maintenance of protein engineering systems
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth in opportunities in emerging markets

CHAPTER 4: PROTEIN ENGINEERING MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Instruments
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Consumables
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Software
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Rational or Site Directed Mutagenesis
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Irrational or Random Mutagenesis
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Monoclonal Antibodies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Insulin
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Erythropoietin
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Interferon
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country
  • 6.6. Others
    • 6.6.1. Key market trends, growth factors and opportunities
    • 6.6.2. Market size and forecast, by region
    • 6.6.3. Market share analysis by country

CHAPTER 7: PROTEIN ENGINEERING MARKET, BY END USER

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Pharmaceutical and Biotechnology Companies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Academic Research Institutes
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Contract Research Organizations
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: PROTEIN ENGINEERING MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Product
    • 8.2.3. Market size and forecast, by Technology Type
    • 8.2.4. Market size and forecast, by Protein Type
    • 8.2.5. Market size and forecast, by End User
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Product
      • 8.2.6.1.2. Market size and forecast, by Technology Type
      • 8.2.6.1.3. Market size and forecast, by Protein Type
      • 8.2.6.1.4. Market size and forecast, by End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Product
      • 8.2.6.2.2. Market size and forecast, by Technology Type
      • 8.2.6.2.3. Market size and forecast, by Protein Type
      • 8.2.6.2.4. Market size and forecast, by End User
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Product
      • 8.2.6.3.2. Market size and forecast, by Technology Type
      • 8.2.6.3.3. Market size and forecast, by Protein Type
      • 8.2.6.3.4. Market size and forecast, by End User
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Product
    • 8.3.3. Market size and forecast, by Technology Type
    • 8.3.4. Market size and forecast, by Protein Type
    • 8.3.5. Market size and forecast, by End User
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Product
      • 8.3.6.1.2. Market size and forecast, by Technology Type
      • 8.3.6.1.3. Market size and forecast, by Protein Type
      • 8.3.6.1.4. Market size and forecast, by End User
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Product
      • 8.3.6.2.2. Market size and forecast, by Technology Type
      • 8.3.6.2.3. Market size and forecast, by Protein Type
      • 8.3.6.2.4. Market size and forecast, by End User
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Product
      • 8.3.6.3.2. Market size and forecast, by Technology Type
      • 8.3.6.3.3. Market size and forecast, by Protein Type
      • 8.3.6.3.4. Market size and forecast, by End User
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Product
      • 8.3.6.4.2. Market size and forecast, by Technology Type
      • 8.3.6.4.3. Market size and forecast, by Protein Type
      • 8.3.6.4.4. Market size and forecast, by End User
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Product
      • 8.3.6.5.2. Market size and forecast, by Technology Type
      • 8.3.6.5.3. Market size and forecast, by Protein Type
      • 8.3.6.5.4. Market size and forecast, by End User
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Product
      • 8.3.6.6.2. Market size and forecast, by Technology Type
      • 8.3.6.6.3. Market size and forecast, by Protein Type
      • 8.3.6.6.4. Market size and forecast, by End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Product
    • 8.4.3. Market size and forecast, by Technology Type
    • 8.4.4. Market size and forecast, by Protein Type
    • 8.4.5. Market size and forecast, by End User
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Product
      • 8.4.6.1.2. Market size and forecast, by Technology Type
      • 8.4.6.1.3. Market size and forecast, by Protein Type
      • 8.4.6.1.4. Market size and forecast, by End User
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Product
      • 8.4.6.2.2. Market size and forecast, by Technology Type
      • 8.4.6.2.3. Market size and forecast, by Protein Type
      • 8.4.6.2.4. Market size and forecast, by End User
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Product
      • 8.4.6.3.2. Market size and forecast, by Technology Type
      • 8.4.6.3.3. Market size and forecast, by Protein Type
      • 8.4.6.3.4. Market size and forecast, by End User
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Product
      • 8.4.6.4.2. Market size and forecast, by Technology Type
      • 8.4.6.4.3. Market size and forecast, by Protein Type
      • 8.4.6.4.4. Market size and forecast, by End User
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Product
      • 8.4.6.5.2. Market size and forecast, by Technology Type
      • 8.4.6.5.3. Market size and forecast, by Protein Type
      • 8.4.6.5.4. Market size and forecast, by End User
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Product
      • 8.4.6.6.2. Market size and forecast, by Technology Type
      • 8.4.6.6.3. Market size and forecast, by Protein Type
      • 8.4.6.6.4. Market size and forecast, by End User
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Product
    • 8.5.3. Market size and forecast, by Technology Type
    • 8.5.4. Market size and forecast, by Protein Type
    • 8.5.5. Market size and forecast, by End User
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Product
      • 8.5.6.1.2. Market size and forecast, by Technology Type
      • 8.5.6.1.3. Market size and forecast, by Protein Type
      • 8.5.6.1.4. Market size and forecast, by End User
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Market size and forecast, by Product
      • 8.5.6.2.2. Market size and forecast, by Technology Type
      • 8.5.6.2.3. Market size and forecast, by Protein Type
      • 8.5.6.2.4. Market size and forecast, by End User
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Market size and forecast, by Product
      • 8.5.6.3.2. Market size and forecast, by Technology Type
      • 8.5.6.3.3. Market size and forecast, by Protein Type
      • 8.5.6.3.4. Market size and forecast, by End User
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Product
      • 8.5.6.4.2. Market size and forecast, by Technology Type
      • 8.5.6.4.3. Market size and forecast, by Protein Type
      • 8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Agilent Technologies, Inc.
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
  • 10.2. Thermo Fisher Scientific Inc.
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. Promega Corporation
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
  • 10.4. New England Biolabs, Inc.
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
  • 10.5. Danaher Corporation
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
    • 10.5.7. Key strategic moves and developments
  • 10.6. Creative Biolabs Limited
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
  • 10.7. Bio-Rad Laboratories, Inc.
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Business performance
  • 10.8. Amgen, Inc.
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. Jena Bioscience GmbH
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
  • 10.10. TAKARA HOLDINGS INC.
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 02. PROTEIN ENGINEERING MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. PROTEIN ENGINEERING MARKET FOR CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. PROTEIN ENGINEERING MARKET FOR SOFTWARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 06. PROTEIN ENGINEERING MARKET FOR RATIONAL OR SITE DIRECTED MUTAGENESIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PROTEIN ENGINEERING MARKET FOR IRRATIONAL OR RANDOM MUTAGENESIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 09. PROTEIN ENGINEERING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. PROTEIN ENGINEERING MARKET FOR INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. PROTEIN ENGINEERING MARKET FOR ERYTHROPOIETIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. PROTEIN ENGINEERING MARKET FOR INTERFERON, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. PROTEIN ENGINEERING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. PROTEIN ENGINEERING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. PROTEIN ENGINEERING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. PROTEIN ENGINEERING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. PROTEIN ENGINEERING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA PROTEIN ENGINEERING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 24. U.S. PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. U.S. PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 27. U.S. PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. CANADA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. CANADA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 31. CANADA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE PROTEIN ENGINEERING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. UK PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. UK PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. UK PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 52. UK PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. ITALY PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. ITALY PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. ITALY PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 56. ITALY PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 70. JAPAN PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. CHINA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 75. CHINA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 76. CHINA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 77. CHINA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. INDIA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 79. INDIA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDIA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDIA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. AUSTRALIA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 83. AUSTRALIA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. AUSTRALIA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 85. AUSTRALIA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA PROTEIN ENGINEERING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 99. BRAZIL PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 101. BRAZIL PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 102. BRAZIL PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. SAUDI ARABIA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. SOUTH AFRICA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH AFRICA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 109. SOUTH AFRICA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH AFRICA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. REST OF LAMEA PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 112. REST OF LAMEA PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022-2032 ($MILLION)
  • TABLE 113. REST OF LAMEA PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA PROTEIN ENGINEERING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 116. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 117. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
  • TABLE 118. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 119. THERMO FISHER SCIENTIFIC INC. : KEY EXECUTIVES
  • TABLE 120. THERMO FISHER SCIENTIFIC INC. : COMPANY SNAPSHOT
  • TABLE 121. THERMO FISHER SCIENTIFIC INC. : PRODUCT SEGMENTS
  • TABLE 122. THERMO FISHER SCIENTIFIC INC. : SERVICE SEGMENTS
  • TABLE 123. THERMO FISHER SCIENTIFIC INC. : PRODUCT PORTFOLIO
  • TABLE 124. THERMO FISHER SCIENTIFIC INC. : KEY STRATERGIES
  • TABLE 125. PROMEGA CORPORATION: KEY EXECUTIVES
  • TABLE 126. PROMEGA CORPORATION: COMPANY SNAPSHOT
  • TABLE 127. PROMEGA CORPORATION: PRODUCT SEGMENTS
  • TABLE 128. PROMEGA CORPORATION: SERVICE SEGMENTS
  • TABLE 129. PROMEGA CORPORATION: PRODUCT PORTFOLIO
  • TABLE 130. NEW ENGLAND BIOLABS, INC.: KEY EXECUTIVES
  • TABLE 131. NEW ENGLAND BIOLABS, INC.: COMPANY SNAPSHOT
  • TABLE 132. NEW ENGLAND BIOLABS, INC.: SERVICE SEGMENTS
  • TABLE 133. NEW ENGLAND BIOLABS, INC.: PRODUCT PORTFOLIO
  • TABLE 134. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 135. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 136. DANAHER CORPORATION: PRODUCT SEGMENTS
  • TABLE 137. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 138. DANAHER CORPORATION: KEY STRATERGIES
  • TABLE 139. CREATIVE BIOLABS LIMITED: KEY EXECUTIVES
  • TABLE 140. CREATIVE BIOLABS LIMITED: COMPANY SNAPSHOT
  • TABLE 141. CREATIVE BIOLABS LIMITED: SERVICE SEGMENTS
  • TABLE 142. CREATIVE BIOLABS LIMITED: PRODUCT PORTFOLIO
  • TABLE 143. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
  • TABLE 144. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
  • TABLE 145. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
  • TABLE 146. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
  • TABLE 147. AMGEN, INC.: KEY EXECUTIVES
  • TABLE 148. AMGEN, INC.: COMPANY SNAPSHOT
  • TABLE 149. AMGEN, INC.: PRODUCT SEGMENTS
  • TABLE 150. AMGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 151. AMGEN, INC.: KEY STRATERGIES
  • TABLE 152. JENA BIOSCIENCE GMBH: KEY EXECUTIVES
  • TABLE 153. JENA BIOSCIENCE GMBH: COMPANY SNAPSHOT
  • TABLE 154. JENA BIOSCIENCE GMBH: PRODUCT SEGMENTS
  • TABLE 155. JENA BIOSCIENCE GMBH: PRODUCT PORTFOLIO
  • TABLE 156. TAKARA HOLDINGS INC.: KEY EXECUTIVES
  • TABLE 157. TAKARA HOLDINGS INC.: COMPANY SNAPSHOT
  • TABLE 158. TAKARA HOLDINGS INC.: PRODUCT SEGMENTS
  • TABLE 159. TAKARA HOLDINGS INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PROTEIN ENGINEERING MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PROTEIN ENGINEERING MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN PROTEIN ENGINEERING MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN PROTEIN ENGINEERING MARKET (2023-2032)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL PROTEIN ENGINEERING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. PROTEIN ENGINEERING MARKET, BY PRODUCT, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR CONSUMABLES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR SOFTWARE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR RATIONAL OR SITE DIRECTED MUTAGENESIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR IRRATIONAL OR RANDOM MUTAGENESIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE, 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR INSULIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR ERYTHROPOIETIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR INTERFERON, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. PROTEIN ENGINEERING MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF PROTEIN ENGINEERING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. PROTEIN ENGINEERING MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 29. U.S. PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. CANADA PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. MEXICO PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. GERMANY PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. FRANCE PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. UK PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. ITALY PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SPAIN PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF EUROPE PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. JAPAN PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. CHINA PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. INDIA PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. AUSTRALIA PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SOUTH KOREA PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. REST OF ASIA-PACIFIC PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. BRAZIL PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. SAUDI ARABIA PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SOUTH AFRICA PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. REST OF LAMEA PROTEIN ENGINEERING MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
  • FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52. COMPETITIVE DASHBOARD
  • FIGURE 53. COMPETITIVE HEATMAP: PROTEIN ENGINEERING MARKET
  • FIGURE 54. TOP PLAYER POSITIONING, 2022
  • FIGURE 55. AGILENT TECHNOLOGIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. AGILENT TECHNOLOGIES, INC.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 57. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. THERMO FISHER SCIENTIFIC INC. : NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. DANAHER CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. AMGEN, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. AMGEN, INC.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 70. AMGEN, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. TAKARA HOLDINGS INC.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. TAKARA HOLDINGS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)